Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2013 Jun;36(6):455-65.
doi: 10.1007/s40264-013-0030-1.

The PREGVAXGRIP Study: A Cohort Study to Assess Foetal and Neonatal Consequences of in Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza

Affiliations
Multicenter Study

The PREGVAXGRIP Study: A Cohort Study to Assess Foetal and Neonatal Consequences of in Utero Exposure to Vaccination Against A(H1N1)v2009 Influenza

F Chavant et al. Drug Saf. .

Abstract

Background: In October 2009, in the context of an A(H1N1)v2009 influenza pandemic, a vaccination campaign was launched in France, in which one of the priority groups was pregnant women, on account of the high risk of developing complications following infection by this virus.

Objective: The aim of this multicentric, prospective, observational study was to assess safety and pregnancy outcomes in a cohort of pregnant women when receiving the A(H1N1)v2009 influenza pandemic vaccine.

Methods: This was a prospective study that followed up pregnant women recruited mainly in vaccination centres and maternity departments. Following the expected delivery date, follow-up data were collected concerning the delivery, the infant, and, if appropriate, the reasons why the pregnancy did not reach its term.

Results: Between 1 November 2009 and 31 March 2010, 2,415 pregnant women were included at the time of vaccination; 97.6 % of women received a vaccine without adjuvant and 2.4 % received an adjuvanted vaccine. Ninety-two (3.9 %) women were vaccinated during the first trimester of pregnancy, 1,090 (46.5 %) during the second trimester, and 1,162 (49.6 %) during the third trimester. One hundred and thirty-three adverse events (5.5 % of women) were reported, of which 12 were unexpected or serious. There were 2,246 (93.0 %) known pregnancy outcomes with 12 spontaneous abortions (0.5 %), 6 stillbirths (0.3 %), and 4 therapeutic abortions (0.2 %). There were 65 neonates with congenital anomalies, among which 31 were major. But only one congenital malformation (1.4 %) was reported for the 92 women vaccinated in their first trimester. Of the women, 93.3 % were delivered full term and 6.7 % preterm. For 96 (4.2 %) neonates, a disorder was reported in the neonatal period and 130 (5.6 %) were transferred to the neonatology department.

Conclusions: This study suggests that exposure to the A(H1N1)v2009 pandemic influenza vaccine during pregnancy does not increase the risk of adverse pregnancy outcomes. However, because of the relatively small number of women exposed during the first trimester, other studies are needed to exclude an increased risk of malformation.

Similar articles

See all similar articles

Cited by 4 articles

References

    1. Am J Epidemiol. 1999 Jun 1;149(11):1025-9 - PubMed
    1. Lancet. 2009 Aug 8;374(9688):451-8 - PubMed
    1. Fertil Steril. 1996 Mar;65(3):503-9 - PubMed
    1. Gynecol Obstet Fertil. 2008 Nov;36(11):1091-100 - PubMed
    1. N Engl J Med. 2009 Nov 12;361(20):1935-44 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback